Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
The date of first ofatumumab prescription claim or other DMT of interest was defined as the index date. No post-index requirements were imposed.
Patients were linked to IQVIA's open source medical claims databases (Dx) to obtain patient clinical characteristics.
The initial data were extracted in October 2020. The data and results were refreshed in April 2021 and July 2021 to allow for assessment of changes in characteristics at 6 and 9 months post-launch.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with ≥ 1 prescription for ofatumumab in the LRx/Dx database were included. The date of the first observed prescription within the index window served as the index date.
-. Patients with a diagnosis of COVID-19 or a COVID-19 vaccination any time during the study period.
